156 / 1068
Polish Trial
n=312
Inclusion
(DRE)
Trans-Tasman
n=326
Inclusion
(ERUS;MRI)
5 x 5 Gy
5-FU CRT
Low
T3-4 Nany
Primary Endpoint
Sphincter Preservation
(15% difference)
T3 Nany
Primary Endpoint
Local Recurrences
(10% difference at 3y)